Bronchiectasis Therapeutics Analysis, Clinical Trials & Results and Developments

Bronchiectasis Therapeutics
Press Release

Bronchiectasis, a chronic airways infection, affects lungs and widens bronchial trees. This leads to gradual loss of mucus clearing ability, which increases growth of bacteria. Bronchiectasis can lead to serious health problems such as respiratory failure, heart failure, and atelectasis. The disease often begins in childhood and can be acquired or congenital. Signs and symptoms of bronchiectasis are excessive tiredness or difficulty in concentrating and breathing, anxiety, cough incontinence, depression, coughing up blood, chest pain, and joint pain. Bronchiectasis can further be diagnosed through chest X-ray, blood tests, computerized tomography (CT) scan, and lung function tests such as bronchoscopy and genetic blood tests.

Companies that are involved in developing therapeutics for bronchiectasis have shown positive clinical results in various phases of drug development. For instance, in 2017, Insmed Incorporated revealed topline results for phase III research of Amikacin Liposome Inhalation Suspension (ALIS) in adult patients suffering from diseases caused by mycobacterium, including bronchiectasis.

Request for sample copy of this report at:

Aradigm Corporation, Bayer AG, Santhera Pharmaceuticals Holding AG, Insmed Incorporated, Zambon S.p.A., and Alitair Pharmaceuticals Inc. are some of the companies involved in the development of bronchiectasis therapeutics.

Bronchiectasis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Raleigh Recorder